The pharmaceutical sector is experiencing a important shift in glucose semaglutide versus tirzepatide care with the emergence of GLP-1 transdermal devices. These innovative methods offer a likely simple choice to needle injections for individuals living with diabetes. By bypassing the need for frequent needles, GLP-1 skin devices promise to improve